ENTA vs. GNFT, ARCT, IRWD, INVA, LQDA, VRNA, GYRE, ARQT, OPK, and BCYC
Should you be buying Enanta Pharmaceuticals stock or one of its competitors? The main competitors of Enanta Pharmaceuticals include Genfit (GNFT), Arcturus Therapeutics (ARCT), Ironwood Pharmaceuticals (IRWD), Innoviva (INVA), Liquidia (LQDA), Verona Pharma (VRNA), Gyre Therapeutics (GYRE), Arcutis Biotherapeutics (ARQT), OPKO Health (OPK), and Bicycle Therapeutics (BCYC). These companies are all part of the "medical" sector.
Genfit (NASDAQ:GNFT) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, community ranking, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.
In the previous week, Genfit and Genfit both had 2 articles in the media. Enanta Pharmaceuticals' average media sentiment score of 1.26 beat Genfit's score of 1.25 indicating that Genfit is being referred to more favorably in the media.
Genfit presently has a consensus price target of $11.00, suggesting a potential upside of 112.36%. Enanta Pharmaceuticals has a consensus price target of $19.00, suggesting a potential upside of 52.37%. Given Enanta Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Genfit is more favorable than Enanta Pharmaceuticals.
2.2% of Genfit shares are held by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are held by institutional investors. 4.2% of Genfit shares are held by insiders. Comparatively, 13.6% of Enanta Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Enanta Pharmaceuticals received 246 more outperform votes than Genfit when rated by MarketBeat users. However, 68.09% of users gave Genfit an outperform vote while only 56.47% of users gave Enanta Pharmaceuticals an outperform vote.
Genfit has higher earnings, but lower revenue than Enanta Pharmaceuticals.
Genfit has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500.
Genfit has a net margin of 0.00% compared to Genfit's net margin of -180.76%. Enanta Pharmaceuticals' return on equity of 0.00% beat Genfit's return on equity.
Summary
Genfit beats Enanta Pharmaceuticals on 10 of the 15 factors compared between the two stocks.
Get Enanta Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ENTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Enanta Pharmaceuticals Competitors List
Related Companies and Tools
